STAAR Surgical Company (STAA) - Net Assets

Latest as of September 2025: $353.78 Million USD

Based on the latest financial reports, STAAR Surgical Company (STAA) has net assets worth $353.78 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($456.36 Million) and total liabilities ($102.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of STAAR Surgical Company to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $353.78 Million
% of Total Assets 77.52%
Annual Growth Rate N/A
5-Year Change 101.47%
10-Year Change 922.85%
Growth Volatility 707.38

STAAR Surgical Company - Net Assets Trend (1988–2024)

This chart illustrates how STAAR Surgical Company's net assets have evolved over time, based on quarterly financial data. Also explore STAAR Surgical Company balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for STAAR Surgical Company (1988–2024)

The table below shows the annual net assets of STAAR Surgical Company from 1988 to 2024. For live valuation and market cap data, see STAA market cap overview.

Year Net Assets Change
2024-12-31 $397.33 Million +2.95%
2023-12-31 $385.95 Million +14.83%
2022-12-31 $336.11 Million +29.99%
2021-12-31 $258.56 Million +31.10%
2020-12-31 $197.22 Million +23.35%
2019-12-31 $159.88 Million +20.73%
2018-12-31 $132.43 Million +208.43%
2017-12-31 $42.94 Million +13.27%
2016-12-31 $37.91 Million -2.42%
2015-12-31 $38.85 Million +4.71%
2014-12-31 $37.10 Million -4.51%
2013-12-31 $38.85 Million +22.40%
2012-12-31 $31.74 Million +7.75%
2011-12-31 $29.46 Million +31.35%
2010-12-31 $22.43 Million +6.44%
2009-12-31 $21.07 Million +31.47%
2008-12-31 $16.03 Million -55.76%
2007-12-31 $36.23 Million +14.06%
2006-12-31 $31.76 Million -21.32%
2005-12-31 $40.37 Million +6.61%
2004-12-31 $37.86 Million +6.89%
2003-12-31 $35.42 Million +15.57%
2002-12-31 $30.65 Million -34.55%
2001-12-31 $46.83 Million -20.18%
2000-12-31 $58.67 Million +10.28%
1999-12-31 $53.20 Million +9.47%
1998-12-31 $48.60 Million +8.48%
1997-12-31 $44.80 Million +22.40%
1996-12-31 $36.60 Million +27.53%
1995-12-31 $28.70 Million +30.45%
1994-12-31 $22.00 Million +83.33%
1993-12-31 $12.00 Million +64.38%
1992-12-31 $7.30 Million +69.77%
1991-12-31 $4.30 Million +4200.00%
1990-12-31 $100.00K +101.25%
1989-12-31 $-8.00 Million -100.00%
1988-12-31 $-4.00 Million --

Equity Component Analysis

This analysis shows how different components contribute to STAAR Surgical Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5457600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $493.00K 0.12%
Other Comprehensive Income $-7.03 Million -1.77%
Other Components $471.45 Million 118.65%
Total Equity $397.33 Million 100.00%

STAAR Surgical Company Competitors by Market Cap

The table below lists competitors of STAAR Surgical Company ranked by their market capitalization.

Company Market Cap
Ji'an Mankun Technology Co. Ltd. A
SHE:301132
$794.84 Million
Beingmate Baby & Child Food Co Ltd
SHE:002570
$794.96 Million
CSBC Corp Taiwan
TW:2208
$795.07 Million
Tejas Networks Limited
NSE:TEJASNET
$795.78 Million
SAF Holland SA
XETRA:SFQ
$794.40 Million
Storytel AB (publ)
ST:STORY-B
$794.34 Million
Playtech plc
F:PL8
$794.34 Million
Regional Container Lines Public Company Limited
BK:RCL
$794.32 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in STAAR Surgical Company's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 385,954,000 to 397,335,000, a change of 11,381,000 (2.9%).
  • Net loss of 20,208,000 reduced equity.
  • Share repurchases of 1,505,000 reduced equity.
  • New share issuances of 2,000 increased equity.
  • Other comprehensive income decreased equity by 2,918,000.
  • Other factors increased equity by 36,010,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-20.21 Million -5.09%
Share Repurchases $1.50 Million -0.38%
Share Issuances $2.00K +0.0%
Other Comprehensive Income $-2.92 Million -0.73%
Other Changes $36.01 Million +9.06%
Total Change $- 2.95%

Book Value vs Market Value Analysis

This analysis compares STAAR Surgical Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.36x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1988-12-31 $-1.60 $27.19 x
1989-12-31 $-2.90 $27.19 x
1990-12-31 $0.02 $27.19 x
1991-12-31 $0.46 $27.19 x
1992-12-31 $0.72 $27.19 x
1993-12-31 $0.96 $27.19 x
1994-12-31 $2.12 $27.19 x
1995-12-31 $2.10 $27.19 x
1996-12-31 $2.65 $27.19 x
1997-12-31 $3.21 $27.19 x
1998-12-31 $3.38 $27.19 x
1999-12-31 $3.59 $27.19 x
2000-12-31 $3.80 $27.19 x
2001-12-31 $2.73 $27.19 x
2002-12-31 $1.78 $27.19 x
2003-12-31 $1.99 $27.19 x
2004-12-31 $1.93 $27.19 x
2005-12-31 $1.70 $27.19 x
2006-12-31 $1.26 $27.19 x
2007-12-31 $1.29 $27.19 x
2008-12-31 $0.54 $27.19 x
2009-12-31 $0.65 $27.19 x
2010-12-31 $0.64 $27.19 x
2011-12-31 $0.80 $27.19 x
2012-12-31 $0.88 $27.19 x
2013-12-31 $1.01 $27.19 x
2014-12-31 $0.97 $27.19 x
2015-12-31 $0.99 $27.19 x
2016-12-31 $0.94 $27.19 x
2017-12-31 $1.05 $27.19 x
2018-12-31 $2.93 $27.19 x
2019-12-31 $3.41 $27.19 x
2020-12-31 $4.11 $27.19 x
2021-12-31 $5.23 $27.19 x
2022-12-31 $6.81 $27.19 x
2023-12-31 $7.81 $27.19 x
2024-12-31 $8.09 $27.19 x

Capital Efficiency Dashboard

This dashboard shows how efficiently STAAR Surgical Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -5.09%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -6.44%
  • • Asset Turnover: 0.62x
  • • Equity Multiplier: 1.28x
  • Recent ROE (-5.09%) is below the historical average (75.44%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1988 0.00% -55.88% 0.42x 0.00x $-3.40 Million
1989 0.00% -97.78% 0.34x 0.00x $-3.60 Million
1990 3500.00% 77.78% 0.42x 106.00x $3.49 Million
1991 -262.79% -262.79% 0.46x 2.19x $-11.73 Million
1992 -69.86% -50.00% 0.80x 1.75x $-5.83 Million
1993 20.83% 12.44% 1.07x 1.57x $1.30 Million
1994 37.73% 30.29% 0.95x 1.31x $6.10 Million
1995 26.13% 21.61% 0.89x 1.35x $4.63 Million
1996 18.85% 16.35% 0.83x 1.40x $3.24 Million
1997 16.52% 17.41% 0.68x 1.39x $2.92 Million
1998 5.03% 4.43% 0.74x 1.54x $-2.37 Million
1999 4.17% 3.73% 0.69x 1.62x $-3.07 Million
2000 -32.33% -35.01% 0.67x 1.37x $-24.75 Million
2001 -31.94% -29.53% 0.76x 1.42x $-19.48 Million
2002 -56.16% -35.56% 1.07x 1.48x $-20.21 Million
2003 -23.73% -16.56% 1.07x 1.34x $-11.88 Million
2004 -29.95% -21.93% 0.99x 1.37x $-15.12 Million
2005 -27.68% -21.78% 0.97x 1.31x $-15.21 Million
2006 -47.37% -26.73% 1.18x 1.50x $-18.22 Million
2007 -44.17% -26.95% 1.10x 1.50x $-19.62 Million
2008 -144.72% -30.97% 1.42x 3.28x $-24.80 Million
2009 -29.43% -8.23% 1.28x 2.79x $-8.31 Million
2010 0.24% 0.10% 1.35x 1.81x $-2.19 Million
2011 4.58% 2.15% 1.28x 1.66x $-1.60 Million
2012 -5.55% -2.76% 1.16x 1.73x $-4.94 Million
2013 1.02% 0.55% 1.17x 1.59x $-3.49 Million
2014 -22.62% -11.19% 1.27x 1.59x $-12.10 Million
2015 -16.82% -8.47% 1.23x 1.62x $-10.42 Million
2016 -32.00% -14.71% 1.26x 1.73x $-15.92 Million
2017 -4.98% -2.36% 1.33x 1.58x $-6.43 Million
2018 3.75% 4.01% 0.74x 1.26x $-8.27 Million
2019 8.79% 9.35% 0.72x 1.30x $-1.94 Million
2020 3.00% 3.62% 0.64x 1.31x $-13.81 Million
2021 10.64% 11.94% 0.67x 1.34x $1.66 Million
2022 11.80% 13.95% 0.68x 1.25x $6.05 Million
2023 5.53% 6.62% 0.66x 1.27x $-17.25 Million
2024 -5.09% -6.44% 0.62x 1.28x $-59.94 Million

Industry Comparison

This section compares STAAR Surgical Company's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $1,863,507,886
  • Average return on equity (ROE) among peers: -17.76%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
STAAR Surgical Company (STAA) $353.78 Million 0.00% 0.29x $794.79 Million
Akoya Biosciences Inc (AKYA) $121.35 Million -35.38% 0.57x $64.44 Million
Align Technology Inc (ALGN) $1.35 Billion 32.89% 0.86x $12.66 Billion
AngioDynamics Inc (ANGO) $517.03 Million -1.36% 0.37x $444.32 Million
AptarGroup Inc (ATR) $2.71 Billion 14.48% 0.94x $7.66 Billion
AtriCure Inc (ATRC) $16.74 Million -22.66% 1.01x $1.44 Billion
Avinger Inc (AVGR) $-73.64 Million 0.00% 0.00x $1.52 Million
Anteris Technologies Global Corp. Common Stock (AVR) $10.52 Million -163.15% 1.04x $156.14 Million
Avantor Inc (AVTR) $5.57 Billion -9.53% 1.12x $5.43 Billion
Azenta Inc (AZTA) $553.69 Million -12.55% 0.24x $1.04 Billion
Baxter International Inc (BAX) $7.87 Billion 19.65% 1.00x $8.85 Billion

About STAAR Surgical Company

NASDAQ:STAA USA Medical Instruments & Supplies
Market Cap
$1.34 Billion
Market Cap Rank
#10195 Global
#2585 in USA
Share Price
$27.19
Change (1 day)
+3.15%
52-Week Range
$16.10 - $28.57
All Time High
$162.68
About

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serve… Read more